Return Peptide Library

MariTide

ALevel 1 evidence

MariTide

GLP-1 and incretin receptor agonists

AI Interpretation of This Peptide Generate Report

Basic Information

Categories

Antibody-Peptide Conjugate

Overview

Amgen's once-monthly bispecific antibody–peptide conjugate demonstrates significant weight loss efficacy in Phase II trials.

Efficacy Rating

Bispecific, GLP-1 Agonist, GIPR Antagonist

Evidence Level

Grade A

Evidence Type

No data available

Confidence

No data available

China Regulatory Status

Cosmetic Ingredient Directory

No data available

Food/Supplements

No data available

Medicine

No data available

Similar Peptide Recommendations

Dulaglutide

Dulaglutide

AGLP-1 and incretin receptor agonists

Weight loss, metabolic health, FDA-approved

Liraglutide

Liraglutide

AGLP-1 and incretin receptor agonists

Weight loss, metabolic health, FDA-approved

Orforglipron

Orforglipron

AGLP-1 and incretin receptor agonists

GLP-1 Agonist, Oral, Weight Loss

Retatrutide

Retatrutide

AGLP-1 and incretin receptor agonists

Weight loss, in research, GLP-1

Disclaimer

The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.